More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$160054399
EPS
-0.02
P/E ratio
--
Price to sales
3.03
Dividend yield
--
Beta
0.465233
Previous close
$3.70
Today's open
$3.65
Day's range
$3.55 - $3.73
52 week range
$2.86 - $6.61
show more
CEO
Linda M. Tharby
Employees
73
Headquarters
Mahwah, NJ
Exchange
NASDAQ Capital Market
Shares outstanding
43375176
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
KORU Is On The Mend
KORU Medical Systems is rated Buy at $3.50, as Q3 results signal recovery from temporary headwinds. KRMD's FY26 guidance was raised, with revenue expected at $48.0M–$48.5M (17–18% growth) and gross margin at 63–64%. Core SCIg business remains strong (+11.2% y/y), gross margin expanded 500bp, and pipeline initiatives support future growth.
Seeking Alpha • Nov 13, 2026

What KORU Medical Systems (KRMD) Said on Its Q3 Earnings Call
KORU Medical Systems NASDAQ: KRMD raised the lower end of its 2026 revenue and gross margin guidance after reporting third-quarter revenue growth of 11%, a second consecutive quarter of positive net income and new distribution agreements in Europe and Africa.
MarketBeat • Nov 11, 2026

KORU Medical Systems, Inc. (KRMD) Q3 2026 Earnings Call Transcript
KORU Medical Systems, Inc. (KRMD) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 11, 2026

KORU Medical Systems Announces Third Quarter 2026 Results Including Second Consecutive Quarter of Positive Net Income and Adjusted EBITDA
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the third quarter ended September 30, 2026. Third Quarter 2026 and Recent Highlights Net revenues grew 11% over the prior year period to $11.6 million; year to date net rev.
Business Wire • Nov 10, 2026

KORU Medical Systems to Participate in Upcoming Investor Conferences
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will participate in the following investor conference: Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. Management is scheduled to present on Novembe.
Business Wire • Nov 4, 2026

KORU Medical Systems to Report Third Quarter 2026 Financial Results on November 10, 2026
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report third quarter 2026 financial results on Tuesday, November 10, 2026. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discus.
Business Wire • Oct 20, 2026

KORU Medical Systems, Inc. (KRMD) Q2 2026 Earnings Call Transcript
KORU Medical Systems, Inc. (KRMD) Q2 2026 Earnings Call Transcript
Seeking Alpha • Aug 6, 2026

KORU Medical Systems Q2 Earnings Call Highlights
KORU Medical Systems NASDAQ: KRMD reported second-quarter revenue of $12 million, up 18% from a year earlier, as domestic patient starts, market-share gains and international demand supported growth. The company also said it achieved positive net income for the first time since 2019 and raised its full-year gross-margin outlook, while narrowing revenue guidance because certain international prefilled-syringe market launches are taking longer to develop than expected.
MarketBeat • Aug 6, 2026

KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2026. The Company also updated guidance for the full year 2026. Second Quarter 2026 and Recent Highlights Net revenues grew 18% over the p.
Business Wire • Aug 5, 2026

KORU Medical Systems, Inc. (KRMD) Q2 Earnings and Revenues Beat Estimates
KORU Medical Systems, Inc. (KRMD) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to break-even earnings per share a year ago.
Zacks Investment Research • Aug 5, 2026

¹ Disclosures

Open an M1 investment account to buy and sell KORU Medical Systems Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.